Johns Hopkins University · FACULTY OF BIOLOGY

AS.410.604 Chap.10 Cancer Genes and the Tumor Environment

- one subject, every graph, every model, every mark
5 Chapters3-page Bible
Our own words - no uploaded lecturer files
Updated for this semester
Chapter 10 of 10 · AS.410.604

Cancer Genes and the Tumor Environment

Separate drive, restraint and context

Activating changes can convert proto-oncogenes into oncogenes, while tumor-suppressor loss removes control of proliferation, repair or death. Fibroblasts, immune cells, vessels and matrix add contextual signals.

Pathway-state, dependency, genetic and microenvironment evidence answer different questions and should remain separate.

Build claims in an evidence ladder

Begin with the exact alteration rather than the word cancer.

A point mutation, amplification, translocation or regulatory change can increase an oncogenic signal, whereas deletion, truncation, silencing or loss of a remaining functional allele can reduce a suppressive function. Then measure the relevant molecular state: Ras nucleotide loading, kinase phosphorylation, transcriptional output, DNA-damage response or apoptotic competence.

A changed state supports pathway involvement but does not yet establish that a cell depends on it. Perturb the candidate with an inhibitor, depletion, restoration or resistant rescue and connect that manipulation to proliferation, survival, invasion or another defined phenotype. Controls should show target engagement and exclude a general toxic effect.

This sequence prevents an association from being promoted directly into a therapeutic conclusion.

Keep the environment mechanistic

Tumour cells interact with fibroblasts, immune cells, endothelial cells, extracellular matrix and soluble factors.

Describe those partners through a specific signal and response: a stromal ligand activates a receptor, matrix stiffness changes integrin signalling, or immune-derived cytokine alters transcription. Conditioned medium tests a soluble contribution, co-culture adds reciprocal communication, and matrix perturbation tests physical context.

If a phenotype appears only in co-culture, the result identifies contextual support but not automatically the responsible factor. Fractionation, neutralising reagents or receptor blockade can narrow the explanation.

Likewise, increased vessel density, immune infiltration or matrix remodelling is descriptive until linked to the tumour-cell behaviour being claimed.

Interpret combinations cautiously

When receptor blockade fails but MEK inhibition works, persistent growth is consistent with a lesion or input downstream of the receptor and upstream of MEK-dependent output. It is not proof of a particular Ras or Raf mutation.

Sequence the candidate gene, measure intermediate states and test whether restoring normal regulation reverses the phenotype. For tumour suppressors, distinguish reduced abundance from loss of function and ask whether one intact copy remains. For oncogenes, distinguish increased protein abundance from constitutive activity.

In treatment reasoning, compare single and combined perturbations with matched doses and proper controls; an enhanced combination response is useful evidence, but synergy requires a defined quantitative model. Close every answer by naming the strongest supported claim and one experiment that would rule out its nearest alternative.

In this chapter

What this chapter covers

  • 01

    Proto-oncogene activation

  • 02

    Tumor-suppressor loss

  • 03

    Constitutive Ras signaling

  • 04

    Angiogenic support

  • 05

    Matrix and stromal signals

Worked example · free

Interpret receptor-independent ERK activity

Q [6 marks]. Ras-GTP and ERK remain high after receptor blockade, while MEK inhibition reduces growth. What is supported? The six-mark allocation is an AskSia revision aid, not an official Johns Hopkins marking scheme.
Cancer signaling can increase drive or remove restraint.Cancer signaling can increase drive or remove restraint. Proto-oncogene activation and tumor-suppressor loss reach growth control through different genetic directions.proto-oncogene gaingrowth signal stuck onsuppressor lossbrake or repair lostmalignant traits
Cancer signaling can increase drive or remove restraint. Proto-oncogene activation and tumor-suppressor loss reach growth control through different genetic directions.
  • 2Identify receptor independence.
  • 2Identify pathway dependence.
  • 2Preserve genetic uncertainty.
The growth signal is receptor independent but remains MEK dependent. An activating Ras change is plausible, yet sequencing and regulator tests are needed.
Sia tip — Constitutive signaling can remain dependent on downstream components.
Glossary

Key terms

Proto Oncogene
A Proto Oncogene can become growth promoting through activating change.
Tumor Suppressor
A Tumor Suppressor restrains proliferation, supports repair or promotes death.
Tumor Microenvironment
The Tumor Microenvironment contains stromal cells, vessels, signals and matrix around a tumor.
FAQ

Cancer Genes and the Tumor Environment FAQ

How do oncogene activation and tumor-suppressor loss differ?

Oncogene activation creates excessive or constitutive growth-promoting activity, often through gain-of-function. Tumor-suppressor loss removes a brake, repair function or death-promoting function. The genetic direction and expected experimental rescue therefore differ.

Does persistent ERK activity prove mutant Ras?

No. Receptor activation, altered Ras regulators, active Raf, reduced phosphatase activity and other changes can converge on ERK. Measure Ras nucleotide state, pathway intermediates and response to selective blocks before naming the driver.

How can the tumor microenvironment support growth?

Fibroblasts and immune cells can release signals, vessels supply oxygen and nutrients, and matrix properties alter integrin signaling. Conditioned-medium, neutralization and matrix perturbation experiments can test whether a contextual factor is necessary or sufficient.

Study strategy

Exam move

Label each claim as genetic alteration, biochemical state, functional dependency or contextual support. Require a matching experiment before moving to the next evidence level. Start a revision sheet with four columns: alteration, molecular readout, perturbation and phenotype. Place receptor blockade, Ras-GTP, MEK inhibition and growth in their proper columns, then write the strongest conclusion that the whole pattern supports.

Repeat with a tumour-suppressor example, keeping abundance separate from function and one-allele loss separate from complete loss. For microenvironment questions, name the partner cell or matrix feature, the signal it supplies and the tumour-cell response. Choose conditioned medium, co-culture or matrix manipulation according to the claim being tested.

Finish by writing one control for target engagement, one for general toxicity and one rescue. On a timed pass, force every answer to end with an evidence limit and the next experiment that distinguishes the two most plausible alternatives.

Working through Cancer Genes and the Tumor Environment in AS.410.604? Sia is AskSia’s AI Biology tutor — ask any AS.410.604 Cancer Genes and the Tumor Environment question and get a clear, step-by-step explanation grounded in how AS.410.604 is taught and assessed. Read this chapter free, then take your hardest questions to Sia.

A+Everything unlocked
Unlocks this Bible + all 8 of your subjects at Johns Hopkins University, plus 1,000+ more Bibles across the AskSia library.
Sia - your AS410604 tutor, unlimited, worked the way the exam marks it
The full 3-page Bible + practice bank with worked solutions
Chrome extension - sync your LMS so Sia knows your deadlines
Bilingual EN / Chinese on every Bible and every Sia answer
$0.99 Trial
30-day money-back · cancel in one tap · how it works